Free Trial Information
BioCentury | Jan 4, 1999
Finance

Two sides of the Euro coin

...than they already are, according to Maarten de Jong, senior associate of corporate finance at Mees...
Read More
BioCentury | Jul 6, 1998
Finance

Pharming's bumper harvest

...and U.K. institutions each will own about 10 percent of the stock. Wim Obbens of Mees...
Read More
BioCentury | May 4, 1998
Finance

UBS alums resurface at Cowen

...triggered the surge in British biotech IPOs. Pharming is recruiting a second bank to join Mees...
Read More
BioCentury | Mar 9, 1998
Company News

Cor management update

(CORR board appointment, see above) Cor Therapeutics Inc. (CORR), South San Francisco, Calif. Business: Cardiovascular Promoted: Charles du Mee to VP of product development, formerly senior director of product development; Ellen Martin to VP of...
Read More
Items per page:
1 - 4 of 4
BioCentury | Jan 4, 1999
Finance

Two sides of the Euro coin

...than they already are, according to Maarten de Jong, senior associate of corporate finance at Mees...
Read More
BioCentury | Jul 6, 1998
Finance

Pharming's bumper harvest

...and U.K. institutions each will own about 10 percent of the stock. Wim Obbens of Mees...
Read More
BioCentury | May 4, 1998
Finance

UBS alums resurface at Cowen

...triggered the surge in British biotech IPOs. Pharming is recruiting a second bank to join Mees...
Read More
BioCentury | Mar 9, 1998
Company News

Cor management update

(CORR board appointment, see above) Cor Therapeutics Inc. (CORR), South San Francisco, Calif. Business: Cardiovascular Promoted: Charles du Mee to VP of product development, formerly senior director of product development; Ellen Martin to VP of...
Read More
Items per page:
1 - 4 of 4